ConductScience.org, home

Paper32268367

Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).

Stiekema LCA and 11 others. Eur Heart J, 2020. Cited by 94 papers, by iCite.

Cite this record

ConductScience Library. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). Papers, record 32268367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32268367

Download JSON
Disease
cardiovascular disorder522 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).
PubMed
Journal
Eur Heart J
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
94
iCite
Relative citation ratio, by iCite
4.33
iCite
Revised in PubMed
2022-10-21
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Stiekema LCALotte C A
2Prange KHMKoen H M
3Hoogeveen RMRenate M
4Verweij SLSimone L
5Kroon JJeffrey
6Schnitzler JGJohan G
7Dzobo KEKim E
8Cupido AJArjen J
9Tsimikas SSotirios
10Stroes ESGErik S G
11de Winther MPJMenno P J
12Bahjat MMahnoush

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Lipoprotein(a)Major topic
MonocytesMajor topic
Apoprotein(a)
Humans
Oligonucleotides
Proprotein Convertase 9

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT02729025Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))Derived from the trialYesClinicalTrials.gov
NCT03070782Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular DiseaseDerived from the trialYesClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in32445566Mechanistic insights into lipoprotein(a): from infamous to 'inflammous'.https://conductscience.org/library/papers/32445566

Source PubMed

Download CSV of comments and corrections

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118423196Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury.Cell2008https://conductscience.org/library/papers/18423196PubMed
230561610
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
Eur Heart J2019https://conductscience.org/library/papers/30561610PubMed
39077376Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.N Engl J Med1997https://conductscience.org/library/papers/9077376PubMed
424333007Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype.Metabolism2014https://conductscience.org/library/papers/24333007PubMed
529926099Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.JAMA Cardiol2018https://conductscience.org/library/papers/29926099PubMed
620706656DAMPening inflammation by modulating TLR signalling.Mediators Inflamm2010https://conductscience.org/library/papers/20706656PubMed
728845751Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.N Engl J Med2017https://conductscience.org/library/papers/28845751PubMed
827764724Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo.Atherosclerosis2016https://conductscience.org/library/papers/27764724PubMed
912432042Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.N Engl J Med2002https://conductscience.org/library/papers/12432042PubMed
1020032323Genetic variants associated with Lp(a) lipoprotein level and coronary disease.N Engl J Med2009https://conductscience.org/library/papers/20032323PubMed
1123727083
Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study.
J Am Coll Cardiol2013https://conductscience.org/library/papers/23727083PubMed
1227496857Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.Circulation2016https://conductscience.org/library/papers/27496857PubMed
1325014686Effects of extended-release niacin with laropiprant in high-risk patients.N Engl J Med2014https://conductscience.org/library/papers/25014686PubMed
1430293769Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.Lancet2018https://conductscience.org/library/papers/30293769PubMed
1517981204Regulation of interferon-gamma during innate and adaptive immune responses.Adv Immunol2007https://conductscience.org/library/papers/17981204PubMed
1628183512A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.J Am Coll Cardiol2017https://conductscience.org/library/papers/28183512PubMed
1729875409Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice.Nature2018https://conductscience.org/library/papers/29875409PubMed
1827665230Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.Lancet2016https://conductscience.org/library/papers/27665230PubMed
1919509380Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.JAMA2009https://conductscience.org/library/papers/19509380PubMed
2028329114PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia.Eur Heart J2017https://conductscience.org/library/papers/28329114PubMed

See all 22 referencesDownload CSV of references

Cited by58

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 94 citations.

PMIDTitleJournalYearIn PapersSource
42878985GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases.Curr Atheroscler Rep2026https://conductscience.org/library/papers/42878985PubMed
42814209The Roles of Lipoprotein(a) in Atherosclerosis - Minding the Knowledge Gaps.Curr Atheroscler Rep2026https://conductscience.org/library/papers/42814209PubMed
42693289Genetic evidence supports the combined targeting of lipoprotein(a) and LDL cholesterol to reduce coronary artery disease risk.Nat Cardiovasc Res2026https://conductscience.org/library/papers/42693289PubMed
41538799Beyond lipids: Systemic effects of lipoprotein apheresis.Transfusion2026https://conductscience.org/library/papers/41538799PubMed
41488100Emerging therapies targeting lipoprotein(a): the next frontier in cardiovascular risk reduction.Front Med (Lausanne)2025https://conductscience.org/library/papers/41488100PubMed
41264184Lipoprotein(a) in Cardiovascular Diseases and Emerging Therapeutic Strategies.Cardiovasc Drugs Ther2026https://conductscience.org/library/papers/41264184PubMed
41217319Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank.J Am Coll Cardiol2025https://conductscience.org/library/papers/41217319PubMed
41103683Influence of LDL cholesterol and Lp(a) on monocytes and macrophages in atherosclerosis.Biochem Med (Zagreb)2025https://conductscience.org/library/papers/41103683PubMed
41054423Monocytes from people with Familial Hypercholesterolaemia are inflammatory, despite statin-treatment.Atheroscler Plus2025https://conductscience.org/library/papers/41054423PubMed
40757148Lipoprotein (a) in primary cardiovascular disease prevention is actionable today.Am Heart J Plus2025https://conductscience.org/library/papers/40757148PubMed
40682836Research advances in current drugs targeting hyperlipidemia (Review).Mol Med Rep2025https://conductscience.org/library/papers/40682836PubMed
40574736Prognostic value of lymphocyte-to-monocyte ratio in patients with endometrial cancer: an updated systematic review and meta-analysis.PeerJ2025https://conductscience.org/library/papers/40574736PubMed
40334781Lipoprotein (a) integrates monocyte-mediated thrombosis and inflammation in atherosclerotic cardiovascular disease.J Lipid Res2025https://conductscience.org/library/papers/40334781PubMed
40322720Lipoprotein(a)-Lowering Drugs: A Mini Review.J Clin Med Res2025https://conductscience.org/library/papers/40322720PubMed
40004172The Interplay Between Immunity, Inflammation and Endothelial Dysfunction.Int J Mol Sci2025https://conductscience.org/library/papers/40004172PubMed
39959304Epigenetic regulation in coronary artery disease: from mechanisms to emerging therapies.Front Mol Biosci2025https://conductscience.org/library/papers/39959304PubMed
39934244Development and validation of a predictive model for carotid atherosclerosis in postmenopausal women.Sci Rep2025https://conductscience.org/library/papers/39934244PubMed
39912915Inflammation, Lp(a) and cardiovascular mortality: results from the LURIC study.Clin Res Cardiol2025https://conductscience.org/library/papers/39912915PubMed
39289929Lipids and Inflammation: Novel Molecular Targets and Therapeutic Implications.Curr Med Chem2025https://conductscience.org/library/papers/39289929PubMed
39031302Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review.Cardiol Ther2024https://conductscience.org/library/papers/39031302PubMed

See all 58 cited byDownload CSV of cited by

Genes20

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
APOB338PubTator's text mininghttps://conductscience.org/library/genes/338NCBI Gene
CCR2729230PubTator's text mininghttps://conductscience.org/library/genes/729230NCBI Gene
CD14929PubTator's text mininghttps://conductscience.org/library/genes/929NCBI Gene
CETP1071PubTator's text mininghttps://conductscience.org/library/genes/1071NCBI Gene
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
CX3CR11524PubTator's text mininghttps://conductscience.org/library/genes/1524NCBI Gene
GBP22634PubTator's text mininghttps://conductscience.org/library/genes/2634NCBI Gene
IFITM210581PubTator's text mininghttps://conductscience.org/library/genes/10581NCBI Gene
IFNA13439PubTator's text mininghttps://conductscience.org/library/genes/3439NCBI Gene
IFNA83445PubTator's text mininghttps://conductscience.org/library/genes/3445NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
IRF13659PubTator's text mininghttps://conductscience.org/library/genes/3659NCBI Gene
JUN3725PubTator's text mininghttps://conductscience.org/library/genes/3725NCBI Gene
LPA4018PubTator's text mininghttps://conductscience.org/library/genes/4018NCBI Gene
MYD884615PubTator's text mininghttps://conductscience.org/library/genes/4615NCBI Gene
PCSK9255738PubTator's text mininghttps://conductscience.org/library/genes/255738NCBI Gene
TLR27097PubTator's text mininghttps://conductscience.org/library/genes/7097NCBI Gene
TLR47099PubTator's text mininghttps://conductscience.org/library/genes/7099NCBI Gene
TLR851311PubTator's text mininghttps://conductscience.org/library/genes/51311NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
EVOLOCUMABCHEMBL2364655Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2364655ChEMBL
PELACARSENCHEMBL4298202Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4298202ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32268367

GET https://conductscience.org/api/papers/v1/32268367/references?page=2